

Chiesi GmbH
Chiesi: A Pharmaceutical Company with Vision
Chiesi: A Pharmaceutical Company with a Vision
editChiesi is a renowned biopharmaceutical company specializing in the development and marketing of innovative medical solutions. The group operates internationally and originated in Italy, where it was founded in 1935.
Key Products and Services
editChiesi focuses on four main therapeutic areas:
- Atemwege (AIR): Specializes in medications for the treatment of respiratory diseases.
- Neonatologie: Products to support newborns, especially premature babies.
- Seltene Erkrankungen (RARE): Treatments for patients with rare diseases.
- Transplantationsmedizin (CARE): Medications for transplanted people as well as self-medication products.
Mission and Values
editChiesi pursues the mission of improving people's quality of life while acting responsibly towards society and the environment. Since 2019, Chiesi has been certified as a B Corp, which underscores its commitment to sustainable corporate governance based on global standards[1][2].
Sustainability Goals and Initiatives
editChiesi aims for Net-Zero emissions by 2035 and is committed to sustainable production and jobs. Numerous initiatives such as moving to a sustainable office building in Hamburg and investing in a new production site in Italy underscore this commitment. Chiesi also supports projects such as Neopedia, an information platform for families of premature babies[1][3][4].
Employees and Presence
editWorldwide, Chiesi employs over 7,000 people in 31 subsidiaries and markets its products in approximately 100 countries. In Germany, the company is based in Hamburg and employs around 400 people[2][4]. Chiesi has repeatedly been recognized as a Top Employer and offers a comprehensive program for career preparation for young people[4].
Further Activities and Goals
editChiesi is also involved in science communication and offers platforms such as the "ATEMWEG Podcast" to share medical information. In addition, the company strives to invest in the future of healthcare through continuous innovation and investments[3][4].